To achieve negative intraoperative margins as much as possible, when tumor resection is limited, patients with defined tumor subtypes may benefit from gene-targeted therapy with PDGFRA or MDM2, especially for those with less differentiated IS. This evidence concerns the gene MDM2 and neoplasm.